Biodistribution, Safety Profile, and Radiation Dosimetry of [<sup>18</sup>F]SYN2, a PET Cardiac Perfusion Tracer, in Healthy Subjects

A first-in-human phase I clinical study aimed to assess the safety profile, radiation dosimetry, and biodistribution of a potential cardiac PET myocardial perfusion imaging tracer, [<sup>18</sup>F]SYN2 (<sup>18</sup>F-labeled acridine derivative), in healthy subjects. <b>Methods:</b> [<sup>18</sup>F]SYN2 intravenous administration with PET imaging was performed on healthy volunteers, and sequential whole-body imaging was performed over 4 h. Blood and urine samples were collected for up to 240 min. Safety follow-up visits took place at 2, 5, and 14 d after the administration. <b>Results:</b> Ten subjects (8 women and 2 men) completed all study procedures. The mean age was 38.1 ± 8.8 y, and the mean body mass index was 22.7 ± 3.0 kg/m<sup>2</sup> The mean administered dose of radioactivity was 258 MBq (range, 246-272 MBq). There were no drug-related adverse events, and the tracer was well tolerated in all subjects. The mean whole-body effective radiation dose for [<sup>18</sup>F]SYN2 was 0.0195 mSv/MBq. The tracer was rapidly taken up by the myocardial wall and cleared from plasma, leading to good image quality within minutes of tracer injection. <b>Conclusion:</b> On the basis of the safety profile, radiation dosimetry, and biodistribution of [<sup>18</sup>F]SYN2, it appears to be a promising agent for clinical PET myocardial perfusion imaging and to warrant further clinical studies.

Authors

Institutions

Publication Details

Journal
Journal of Nuclear Medicine
Published
2025-03-06
DOI
https://doi.org/10.2967/jnumed.124.268872
Citations
3
Primary Topic
Cardiac Imaging and Diagnostics
Type
article
Field-Weighted Citation Impact
4.08
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Biodistribution, Safety Profile, and Radiation Dosimetry of [18F]SYN2, a PET Cardiac Perfusion Tracer, in Healthy Subjects

Leszek Królicki, Seweryn Krajewski, Jacek Bil, Mouaz Husayn Al-Mallah et al.
3 citations
Journal of Nuclear Medicine
Cardiac Imaging and Diagnostics
4.08
article

Biodistribution, Safety Profile, and Radiation Dosimetry of [18F]SYN2, a PET Cardiac Perfusion Tracer, in Healthy Subjects

Leszek Królicki, Seweryn Krajewski, Jacek Bil, Mouaz Husayn Al-Mallah, Łukasz Steczek, Panithaya Chareonthaitawee, Małgorzata Kobylecka, Tuula Tolvanen, Mirosław Dziuk, Magdalena Kostkiewicz, Cezary Kozanecki, Juhani Knuuti, Kari K. Kalliokoski, Prem Soman, Piotr J. Slomka, Joanna Włostowska, Joanna Towpik, Przemysław Kozanecki, Karina Gotowicz, Timothy M. Bateman
article en
3 citations

Abstract

A first-in-human phase I clinical study aimed to assess the safety profile, radiation dosimetry, and biodistribution of a potential cardiac PET myocardial perfusion imaging tracer, [<sup>18</sup>F]SYN2 (<sup>18</sup>F-labeled acridine derivative), in healthy subjects. <b>Methods:</b> [<sup>18</sup>F]SYN2 intravenous administration with PET imaging was performed on healthy volunteers, and sequential whole-body imaging was performed over 4 h. Blood and urine samples were collected for up to 240 min. Safety follow-up visits took place at 2, 5, and 14 d after the administration. <b>Results:</b> Ten subjects (8 women and 2 men) completed all study procedures. The mean age was 38.1 ± 8.8 y, and the mean body mass index was 22.7 ± 3.0 kg/m<sup>2</sup> The mean administered dose of radioactivity was 258 MBq (range, 246-272 MBq). There were no drug-related adverse events, and the tracer was well tolerated in all subjects. The mean whole-body effective radiation dose for [<sup>18</sup>F]SYN2 was 0.0195 mSv/MBq. The tracer was rapidly taken up by the myocardial wall and cleared from plasma, leading to good image quality within minutes of tracer injection. <b>Conclusion:</b> On the basis of the safety profile, radiation dosimetry, and biodistribution of [<sup>18</sup>F]SYN2, it appears to be a promising agent for clinical PET myocardial perfusion imaging and to warrant further clinical studies.

Journal of Nuclear MedicineVol. 66(4)
Centrum Badań Kosmicznych (PL), Jagiellonian University (PL), National Academy of Medicine (US), Cedars-Sinai Medical Center (US), Synlab Czech (Czechia) (CZ), Houston Methodist (US), Mayo Clinic (US), Saint Luke's Health System (US), Medical University of Warsaw (PL), Turku University Hospital (FI), John Paul II Hospital (PL), Turku PET Centre (FI), Ministry of Interior and Administration (PL), University of Pittsburgh Medical Center (US), Institute of Cardiology (PL), University of Warsaw (PL)
Good health and well-being
Openalex Percentile: Top 7%
Cardiac Imaging and Diagnostics
4.08
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.